Co-Authors
This is a "connection" page, showing publications co-authored by THOMAS WESTBROOK and JEFFREY ROSEN.
Connection Strength
0.693
-
Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeutics. Cancer Res Commun. 2021 12; 1(3):178-193.
Score: 0.213
-
The oncogenic STP axis promotes triple-negative breast cancer via degradation of the REST tumor suppressor. Cell Rep. 2014 Nov 20; 9(4):1318-32.
Score: 0.130
-
Plk2 regulates mitotic spindle orientation and mammary gland development. Development. 2014 Apr; 141(7):1562-71.
Score: 0.124
-
Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer. Cell. 2021 01 21; 184(2):384-403.e21.
Score: 0.050
-
Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms. Nat Cell Biol. 2019 09; 21(9):1113-1126.
Score: 0.045
-
Erratum: Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation. Nat Cell Biol. 2016 06 28; 18(7):822.
Score: 0.036
-
Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation. Nat Cell Biol. 2016 06; 18(6):632-44.
Score: 0.036
-
The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. Cancer Cell. 2015 Feb 09; 27(2):193-210.
Score: 0.033
-
The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo. Proc Natl Acad Sci U S A. 2011 Mar 01; 108(9):3665-70.
Score: 0.025